Concepedia

Publication | Closed Access

Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced Cancer

DOI

639

Citations

0

References

1993

Year

S A Rosenberg, Michael T. Lotze, Jin‐Hao Yang, Suzanne L. Topalian, A. E. Chang, Douglas J. Schwartzentruber, Paul Aebersold, S.F. Leitman, W. Marston Linehan, Claudia A. Seipp,
JNCI Journal of the National Cancer Institute

Abstract

As these studies continue, efforts are underway to develop improved immunotherapies using tumor-infiltrating lymphocytes (TIL) and gene-modified TIL.